Harbor Spring Capital LLC lifted its stake in Masimo Co. (NASDAQ:MASI – Free Report) by 14.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,300 shares of the medical equipment provider’s stock after buying an additional 9,061 shares during the quarter. Masimo comprises 6.5% of Harbor Spring Capital LLC’s portfolio, making the stock its 4th biggest holding. Harbor Spring Capital LLC owned 0.13% of Masimo worth $11,568,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. American Century Companies Inc. lifted its holdings in Masimo by 2.3% during the first quarter. American Century Companies Inc. now owns 8,799 shares of the medical equipment provider’s stock valued at $1,281,000 after purchasing an additional 194 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in shares of Masimo by 24.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 59,540 shares of the medical equipment provider’s stock valued at $9,049,000 after buying an additional 11,543 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Masimo by 3.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,526 shares of the medical equipment provider’s stock worth $32,977,000 after buying an additional 8,501 shares during the period. Canada Pension Plan Investment Board increased its stake in Masimo by 1,011.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 2,390 shares of the medical equipment provider’s stock worth $348,000 after buying an additional 2,175 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Masimo by 1.5% during the first quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock valued at $695,050,000 after acquiring an additional 71,918 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
MASI has been the subject of a number of recent analyst reports. Raymond James lowered Masimo from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 8th. Needham & Company LLC cut their price objective on shares of Masimo from $136.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. StockNews.com downgraded shares of Masimo from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Finally, Wells Fargo & Company dropped their target price on shares of Masimo from $110.00 to $81.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $122.00.
Masimo Price Performance
Shares of NASDAQ MASI traded down $0.43 during midday trading on Tuesday, reaching $94.26. 26,105 shares of the stock traded hands, compared to its average volume of 678,931. Masimo Co. has a one year low of $75.22 and a one year high of $198.00. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.14 and a quick ratio of 1.13. The company’s 50 day moving average is $86.83 and its 200 day moving average is $122.29. The stock has a market capitalization of $4.98 billion, a PE ratio of 57.74 and a beta of 0.88.
Masimo (NASDAQ:MASI – Get Free Report) last posted its earnings results on Tuesday, November 7th. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04. Masimo had a net margin of 4.19% and a return on equity of 14.18%. The firm had revenue of $478.90 million for the quarter, compared to the consensus estimate of $498.73 million. During the same period in the previous year, the firm posted $1.00 EPS. The business’s quarterly revenue was down 12.8% on a year-over-year basis. On average, equities research analysts anticipate that Masimo Co. will post 2.93 earnings per share for the current year.
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
- Five stocks we like better than Masimo
- What Makes a Stock a Good Dividend Stock?
- Zoom Video Communications: A tech phoenix ready to rise
- How to Calculate Retirement Income: MarketBeat’s Calculator
- The only two airline stocks worth buying: One is a Goldman pick
- What Is Dividend Yield and How Do You Calculate It?
- Ride the momentum: Apparel stocks soaring at 52-week highs
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.